Brokerages expect Immunic (NASDAQ:IMUX) to report earnings of ($0.80) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Immunic’s earnings. The lowest EPS estimate is ($0.86) and the highest is ($0.73). Immunic posted earnings of ($1.52) per share in the same quarter last year, which would indicate a positive year over year growth rate of 47.4%. The firm is expected to issue its next quarterly earnings results on Thursday, August 13th.
On average, analysts expect that Immunic will report full year earnings of ($2.93) per share for the current fiscal year, with EPS estimates ranging from ($3.25) to ($2.67). For the next year, analysts expect that the company will report earnings of ($3.62) per share, with EPS estimates ranging from ($4.53) to ($3.01). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Immunic.
Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.17.
Shares of IMUX stock traded up $0.70 during trading hours on Tuesday, hitting $12.69. The company had a trading volume of 281,200 shares, compared to its average volume of 121,195. Immunic has a 12 month low of $4.19 and a 12 month high of $19.05. The firm has a market capitalization of $153.39 million, a price-to-earnings ratio of -3.44 and a beta of 3.15. The firm’s fifty day moving average is $9.27 and its 200 day moving average is $8.23.
A hedge fund recently raised its stake in Immunic stock. Wells Fargo & Company MN boosted its position in Immunic (NASDAQ:IMUX) by 78.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,814 shares of the company’s stock after buying an additional 4,769 shares during the period. Wells Fargo & Company MN owned approximately 0.08% of Immunic worth $65,000 at the end of the most recent quarter. Institutional investors and hedge funds own 16.86% of the company’s stock.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Read More: Marijuana Stocks Future Looks Bright
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.